R L Goetgebuer1, C J van der Woude2, L de Ridder3, M Doukas4, A C de Vries2. 1. Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. r.goetgebuer@erasmusmc.nl. 2. Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 3. Department of Pediatric Gastroenterology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 4. Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Abstract
BACKGROUND AND AIM: Epstein-Barr virus (EBV) is a proposed trigger in the etiopathogenesis of inflammatory bowel disease (IBD) and is associated with lymphoproliferative diseases. Nevertheless, testing for EBV DNA in the intestinal mucosa and screening for EBV infection before initiation of a drug therapy are not routinely performed. The aim of this article is to increase awareness of the relevance of EBV infection in specific clinical situations. METHODS: In this short communication, we describe the disease course of three IBD patients with EBV infection, varying from EBV reactivation during disease flare up to a trigger of EBV-related mucocutaneous ulcer (EBV-MCU) and haemophagocytic lymphohistiocytosis (HLH). RESULTS: Our first patient was diagnosed with EBV reactivation-associated severe colitis and showed a rapid clinical improvement after induction therapy with infliximab and azathioprine. Without antiviral treatment, the patient remained in complete remission and no complications of EBV were seen. After diagnosing EBV-MCU in the second patient, immunosuppressive medication was discontinued and four infusions of rituximab resulted in a rapid clinical recovery and eventually complete response. After discontinuation of the immunosuppression in our last patient with haemophagocytic lymphohistiocytosis, treatment with a combination of corticosteroid and antiviral therapy resulted in a complete recovery over a time span of several weeks. CONCLUSION: EBV infection has a wide variety of potentially life-threatening clinical manifestations in IBD patients. Testing for EBV in case of a flare up and screening for EBV before the start of immunosuppressive therapy will create awareness for EBV-related symptoms or complications during follow-up.
BACKGROUND AND AIM: Epstein-Barr virus (EBV) is a proposed trigger in the etiopathogenesis of inflammatory bowel disease (IBD) and is associated with lymphoproliferative diseases. Nevertheless, testing for EBV DNA in the intestinal mucosa and screening for EBV infection before initiation of a drug therapy are not routinely performed. The aim of this article is to increase awareness of the relevance of EBV infection in specific clinical situations. METHODS: In this short communication, we describe the disease course of three IBDpatients with EBV infection, varying from EBV reactivation during disease flare up to a trigger of EBV-related mucocutaneous ulcer (EBV-MCU) and haemophagocytic lymphohistiocytosis (HLH). RESULTS: Our first patient was diagnosed with EBV reactivation-associated severe colitis and showed a rapid clinical improvement after induction therapy with infliximab and azathioprine. Without antiviral treatment, the patient remained in complete remission and no complications of EBV were seen. After diagnosing EBV-MCU in the second patient, immunosuppressive medication was discontinued and four infusions of rituximab resulted in a rapid clinical recovery and eventually complete response. After discontinuation of the immunosuppression in our last patient with haemophagocytic lymphohistiocytosis, treatment with a combination of corticosteroid and antiviral therapy resulted in a complete recovery over a time span of several weeks. CONCLUSION:EBV infection has a wide variety of potentially life-threatening clinical manifestations in IBDpatients. Testing for EBV in case of a flare up and screening for EBV before the start of immunosuppressive therapy will create awareness for EBV-related symptoms or complications during follow-up.
Authors: Vincent F Biank; Mehul K Sheth; Julie Talano; David Margolis; Pippa Simpson; Subra Kugathasan; Michael Stephens Journal: J Pediatr Date: 2011-06-30 Impact factor: 4.406
Authors: J F Rahier; F Magro; C Abreu; A Armuzzi; S Ben-Horin; Y Chowers; M Cottone; L de Ridder; G Doherty; R Ehehalt; M Esteve; K Katsanos; C W Lees; E Macmahon; T Moreels; W Reinisch; H Tilg; L Tremblay; G Veereman-Wauters; N Viget; Y Yazdanpanah; R Eliakim; J F Colombel Journal: J Crohns Colitis Date: 2014-03-06 Impact factor: 9.071
Authors: Julie L Ryan; You-Jun Shen; Douglas R Morgan; Leigh B Thorne; Shannon C Kenney; Ricardo L Dominguez; Margaret L Gulley Journal: Dig Dis Sci Date: 2012-03-13 Impact factor: 3.199
Authors: Stefan D Dojcinov; Girish Venkataraman; Mark Raffeld; Stefania Pittaluga; Elaine S Jaffe Journal: Am J Surg Pathol Date: 2010-03 Impact factor: 6.394
Authors: Laurent Beaugerie; Nicole Brousse; Anne Marie Bouvier; Jean Frédéric Colombel; Marc Lémann; Jacques Cosnes; Xavier Hébuterne; Antoine Cortot; Yoram Bouhnik; Jean Pierre Gendre; Tabassome Simon; Marc Maynadié; Olivier Hermine; Jean Faivre; Fabrice Carrat Journal: Lancet Date: 2009-11-07 Impact factor: 79.321